Italian Survey on the Use of Anti-Inflammatory Drugs in Osteoarthritis

Abstract

Osteoarthritis (OA) is the most common painful arthritic disease in adults, causes severe disability and worsens the quality of life of the patients. The aim of this survey, carried out on 147 Italian orthopedic doctors who attended an ISIAT (International Symposium Intra Articular Treatment) educational course in Barcelona, was to investigate some aspects of daily clinical practice in the management of OA: the most used pharmacological treatments, compliance to the most important Guidelines, the advantages of COXIBs in this setting and pharmacoeconomic aspects. The main results of this survey are: a) inflammation has become the main target in OA; b) Guidelines are a useful and valid tool for daily clinical practice; c) acetaminophen is no longer a valid therapeutical option for OA patients; d) anti-inflammatory drugs (NSAIDs and COXIBs) have a primary role in the management of OA, due to their dual activity (anti-inflammatory and analgesic); e) selectivity of COXIBs for COX-2 is very important; f) within the COXIB class, the therapeutic value of etoricoxib has been widely recognized, especially in terms of safety and cost/benefit ratio.

Keywords

NSAIDs COXIB etoricoxib ostheoartritis survey

References

Stam

Jansen

Taylor

. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: A mixed treatment comparison. Open Rheumatol J 2012; 6:6–20.

Gupta

Hawker

Laporte

. The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition. Rheumatology (Oxford) 2005; 44:1531–37.

Riendeau

Percival

Brideau

. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase–2. J Pharmacol Exp Ther 2001; 296(2):558–66.

Hochberg

Altaian

April

. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64(4):465–74.

Jevsevar

Brown

Jones

. The American Academy of Orthopaedic Surgeons evidence-based guideline on: Treatment of osteoarthritis of the knee, 2nd edition. J Bone Joint Surg Am 2013; 95(20): 1885–86.

Jordan

Arden

Doherty

. EULAR Recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62(12): 1145–55.

Zhang

Doherty

Arden

. EULAR evidence based recommendations for the management of hip osteoarthritis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64(5):669–81.

Zhang

Doherty

Leeb

. EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66(3):377–88.

Stam

Jansen

Taylor

. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: A mixed treatment comparison. Open Rheumatol J 2012; 6:6–20.

10.

Moore

Derry

Peloso

Gammaitoni

Wang

. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: Bridging a gap between clinical trials and clinical practice. Ann Rheum Dis 2010; 69(2):374–9.

11.

Lin

Cheng

Wang

. Etoricoxib improves pain, function and quality of life: Results of a real-world effectiveness trial. Int J Rheum Dis 2010; 13(2): 144–50.

12.

Moore

Deny

McQuay

. Cyclooxygenase–2 selective inhibitors and nonsteroidal anti-inflammatory drugs: Balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007; 8:73.